- Home
- INBK vs IMAB Comparison
INBK vs IMAB Comparison
Compare INBK & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBK
- IMAB
- Stock Information
- Founded
- INBK 1999
- IMAB 2014
- Country
- INBK United States
- IMAB United States
- Employees
- INBK N/A
- IMAB N/A
- Industry
- INBK Major Banks
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- INBK Finance
- IMAB Health Care
- Exchange
- INBK Nasdaq
- IMAB Nasdaq
- Market Cap
- INBK 196.2M
- IMAB 200.9M
- IPO Year
- INBK N/A
- IMAB 2020
- Fundamental
- Price
- INBK $21.92
- IMAB $3.41
- Analyst Decision
- INBK Hold
- IMAB Strong Buy
- Analyst Count
- INBK 3
- IMAB 3
- Target Price
- INBK $30.67
- IMAB $6.33
- AVG Volume (30 Days)
- INBK 66.8K
- IMAB 3.4M
- Earning Date
- INBK 07-23-2025
- IMAB 05-15-2025
- Dividend Yield
- INBK 1.10%
- IMAB N/A
- EPS Growth
- INBK N/A
- IMAB N/A
- EPS
- INBK 1.76
- IMAB N/A
- Revenue
- INBK $106,219,000.00
- IMAB N/A
- Revenue This Year
- INBK $5.81
- IMAB N/A
- Revenue Next Year
- INBK $21.76
- IMAB N/A
- P/E Ratio
- INBK $12.36
- IMAB N/A
- Revenue Growth
- INBK 4.74
- IMAB N/A
- 52 Week Low
- INBK $19.54
- IMAB $0.60
- 52 Week High
- INBK $43.27
- IMAB $4.18
- Technical
- Relative Strength Index (RSI)
- INBK 30.93
- IMAB 68.09
- Support Level
- INBK $21.58
- IMAB $1.65
- Resistance Level
- INBK $23.03
- IMAB $4.18
- Average True Range (ATR)
- INBK 1.08
- IMAB 0.38
- MACD
- INBK -0.31
- IMAB 0.16
- Stochastic Oscillator
- INBK 12.46
- IMAB 69.57
About INBK First Internet Bancorp
First Internet Bancorp is a bank holding company. Through its subsidiaries, it provides commercial real estate (CRE) lending, including nationwide single tenant lease financing and commercial and industrial (C&I) lending, including business banking or treasury management services. The company offers its products and services through the internet and does not have any branches. With operations organized into a single segment called the Commercial Banking segment, it also provides retail banking services.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).